Sponsored

Tara Graff, DO, Talks About Acalabrutinib and How the CLL Treatment Landscape has Evolved

 

In this video, Dr Graff, Mission Cancer and Blood, Des Moines, Iowa, talks about how the treatment landscape for chronic lymphocytic leukemia (CLL) has evolved in recent years, especially with the introduction of acalabrutinib (Calquence; AstraZeneca).

Stay in the know.
OncNet Newsletter